開立醫療(300633.SZ):預計2025年微創外科業務收入將取得較大同比增長
格隆匯5月16日丨開立醫療(300633.SZ)於近期投資者關係活動表示,2024年,在市場環境不利的情況下,公司微創外科產品線業務收入取得30%的增長,2025年一季度中標更是取得超過翻倍的增長,呈現出快速增長的態勢,公司預計2025年微創外科業務收入將取得較大同比增長,業務線全年虧損額有望縮小。公司微創外科業務目前仍處於起步階段,研發、市場投入較大,隨着收入規模快速增長,預計業務線實現盈虧平衡的時間越來越近。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.